Analytics firm predicts global psoriasis market to grow twofold by 2030

UK-based analytics firm Globaldata estimates that the market for psoriasis treatments will grow from USD 14.2bn to USD 27.5bn before 2030 – this growth will be based on eight upcoming drug candidates.

Photo: Merck KGaA / PR

The international market for drugs against the skin disease psoriasis will annually grow by 6.8 percent on average by 2030, when the market will total USD 27.5bn, UK-based analytics firm Globaldata reports in a press release.

Seven of the biggest markets have been included in the assessment: US, France, Germany, Italy, Spain, UK and Japan.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Latest news

See all jobs